ABPI issues third version of its biosimilar position paper

May 15, 2014 12:00 PM

The Association of the British Pharmaceutical Industry (ABPI) has launched the third edition of its position paper on biosimilar medicines, which makes seven recommendations covering areas where action is needed by regulators, HTA agencies, NHS commissioners and NHS healthcare professionals who prescribe or dispense biosimilar medicines.

The recommendations highlight the importance of:

  • Robust patient safety monitoring; to enable compliance with EU pharmacovigilance legislation
  • Clear guidance and information to educate prescribers and patients  to ensure  they  are aware of the important differences between biological medicines  and chemically developed medicines

The full list of recommendations are highlighted below and more detail on each recommendation can be found in the ABPI position paper which can be viewed here:

Recommendation 1: All biological/biosimilar medicines should be prescribed by brand name and not by International Non-proprietary Name (INN).

Recommendation 2: Automatic substitution is not appropriate for biological medicines including biosimilars.  A biological medicine including a biosimilar, must only be substituted under the direct supervision and with the consent of the treating physician.

Recommendation 3: Patients should be kept fully informed about their medication and should be consulted if any changes to their treatment are made.

Recommendation 4: The SmPC for a biosimilar medicine should clearly indicate the source of information contained within it, such as relevant data from its clinical development programme and clinical data derived from the originator or reference biological medicine.

Recommendation 5: Biosimilar medicines should be subject to health technology assessment processes in the UK.

Recommendation 6: Tenders which are undertaken involving biological medicines should not seek to source a single product only.

Recommendation 7: Extrapolation of indications for biosimilar products should be evaluated by regulators on a case by case basis.

Commenting on the publication of the position paper, ABPI Director of Value and Access Paul Catchpole said:

“It is important that both patients and prescribers have a full understanding of the differences between biosimilar medicines and more traditional, chemically produced medicines. This should happen at every stage of a patient’s treatment journey, particularly if there are changes being made to the medicines they receive. The ABPI position paper provides an authoritative list of recommendations to inform the NHS and regulators on the appropriate use of these medicines, and to help ensure patients who would benefit from biosimilar medicines can get appropriate access to them.”

The ABPI and its Biosimilars Group (BSG) are developing a suite of materials to further inform stakeholders and answer frequently asked questions to enhance understanding of biological and biosimilar medicines. These will be made available on the ABPI website later this month.

Source: ABPI press release

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!